COMPARATIVE STUDY BETWEEN INTRATHECAL FENTANYL AND MIDAZOLAM AS ADJUVANT TO LOCAL ANESTHETICS IN SPINAL ANESTHESIA IN ELECTIVE CESEAREAN SECTION IN POST-OPERATIVE ANESTHESIA AND POST-OPERATIVE ANALGESIA


ABSTRACT:

Background: Subarachnoid block achieved a wide spread popularity as a simple and effective method of anesthesia for elective cesarean sections. Among the local anesthetics, bupivacaine is the most commonly used drug for subarachnoid block.

Aim of the Work: This study was conducted to evaluate and compare the effects of intrathecal midazolam and fentanyl as additives to intrathecal hyperbaric bupivacaine with regards to onset and duration of sensory block, duration of complete and effective analgesia and side effects associated with the drug.

Patients and Methods: This study included 90 women aged between 18-35 years scheduled to undergo elective cesarean section under spinal anesthesia. Patients were subdivided randomly into 3 groups (30 patients each) on the basis of the adjuvant added to the anesthetic used; group A (Fentanyl + bupivacaine), group B (Midazolam + bupivacaine) and group C (Bupivacaine).

Results: Demographic data did not differ between the three study groups (p > 0.05). Group A showed a significantly earlier onset of sensory block (p =0.005), motor block (p = 0.009), as well as late regression to L1 sensory level (p <0.001). Additionally, longer analgesia (p < 0.05) and longer time before the first call for analgesics (p = 0.005) was associated with group A. The required dose of paracetamol and pethidine within the first day were significantly lower in group A and group B in comparison to group C. However, complications encountered did not differ between the three study groups (p > 0.05). Also, the state of the neonates didn’t show significant difference between the three groups.

Conclusion: Intrathecal adjuvants are associated with improving out comes after CS as revealed by delayed onset and longer duration of sensory and motor block in addition to longer duration of complete and effective analgesia. Intrathecal fentanyl revealed better outcomes in terms of delayed onset and longer duration of sensory and motor block in addition to longer duration of complete and effective analgesia as compared with midazolam.

Keywords: Intrathecal Fentanyl, Midazolam, Local Anesthetics, Spinal Anesthesia, Elective Cesearean Section, Post-Operative Anesthesia, Post-Operative Analgesia.
INTRODUCTION:

Spinal or intrathecal anesthesia has a long history of success and more popular, mostly because of an increasing number of ambulatory procedures and interventions, for which the ideal spinal anesthetic would provide rapid and adequate surgical anesthesia together with early ambulation and early discharge\(^1\).

More studies on bupivacaine have shown that it produces predictable and reliable spinal anesthesia for surgery\(^2\).

Various intrathecal adjuvants to local anesthetics are used. When local anesthetics are combined with opioids, the duration of analgesia is prolonged\(^3\).

Fentanyl, a short-acting lipophilic opioid, is known to augment the quality of subarachnoid block. It was also shown that the addition of fentanyl to hyperbaric ropivacaine increased the intraoperative quality of spinal anesthesia in patients undergoing anorectal surgery, cesarean section, and transurethral resection of the prostate\(^4\).

However, worrisome adverse effects such as pruritus, urinary retention, postoperative vomiting, and respiratory depression limit the use of opioids\(^5\).

Midazolam is a benzodiazepine with unique properties when compared with other benzodiazepines\(^6\).

It is water soluble in its acid formulation but is highly lipid soluble in vivo. It has been reported to have a spinally mediated antinociceptive effect. Previous studies have shown that intrathecal administration of midazolam added to bupivacaine improves the duration and quality of spinal anesthesia\(^5\).

AIM OF THE WORK:

This study is undertaken to evaluate and compare the effects of intrathecal midazolam (2 mg) and fentanyl (25 micrograms) as additives to intrathecal hyperbaric bupivacaine (0.5 %) with regards to: onset and duration of sensory block, duration of complete and effective analgesia, side effects associated with the drug.

PATIENTS AND METHODS:

- **Type of Study:** Prospective randomized double-blind study.
- **Study Setting:** Ain Shams University Hospital, Cairo, Egypt.
- **Study Period:** From July 2019 to January 2020.
- **Study Population:**

  The study included 90 patients scheduled for elective CS under SA and fulfilling all the inclusion criteria were enrolled in the study and randomly allocated into three equal groups of 30 each.

  Patient Method: patients were subdivided randomly into 3 groups (30 patients each) on the basis of the adjuvant added to the local anesthetic used.

  1. **Group (A):** 2 ml of hyperbaric bupivacaine 0.5% + 0.25 ml of fentanyl (12.5 μg) + 0.25 ml normal saline.
  2. **Group (B):** 2 ml of hyperbaric bupivacaine 0.5% + 0.4 ml of midazolam (2mg) + 0.1 ml of normal saline.
  3. **Group (C):** 2 ml of hyperbaric bupivacaine 0.5% + 0.5 ml of normal saline.

**Selection criteria for cases:**

**Inclusion Criteria:**

1. ASA physical status I and ASA II
2. Age from 18-35 years
3. Scheduled to undergo elective cesarean section under spinal anesthesia.

**Exclusion Criteria:**

1. ASA III or IV patients.
2. Patients refuse spinal anesthesia.
3. Patients physically dependent on narcotics or benzodiazepine.
4. Patients with history of drug allergy to fentanyl and midazolam
5. Patients with gross spinal abnormality, localized skin sepsis, haemorrhagic diathesis or neurological involvement/diseases and any contraindication for spine.
6. Head injury cases.
7. Patients with cardiac, pulmonary, hepatic or renal disorders.
8. Patients with peripheral neuropathy.
9. Patients having inadequate subarachnoid blockade and who are later supplemented by general anesthesia.
10. Chronic pain at puncture site.
11. Patients who are unable to communicate.

Patients Consent:
A written informed consent was obtained from all participants before inclusion in the study, explaining the value of the study, plus the procedures details.

Ethical consideration:
The whole study design was approved by the Institutional review board, Faculty of Medicine, Ain -Shams University. Confidentiality and personal privacy will be respected in all levels of the study. Patients feel free to withdraw from the study at any time without any consequences. Collected data will not be used for any other purpose.

Patients:
In the operating room, a wide bore peripheral intravenous access was secured with 18G cannula. On arrival to the operating room, routine monitoring devices were attached and baseline blood pressure, ECG and pulse oximetry values were recorded. All patients were preloaded with Ringer’s lactate solution at 15 ml/kg before SA. Dural puncture was performed at L3–L4 interspace with a 25G spinal needle in the left lateral decubitus position by an anesthesiologist who was not involved in the patient care.

The patients were randomly allocated into three groups to receive one of the medications intrathecally. The study solutions were constituted as mentioned before. Midazolam used as adjuvant to spinal anesthesia is available in our country in 5 mg/ml concentrations. In this study, we used 5 mg/ml concentration. Fentanyl is available as 50 μg/ml. After injection of the study solution, the patients were turned to the supine position with a 15 degree wedge under the right hip for left uterine displacement. Oxygen (3 L/min) was administered via facemask. Cardio-respiratory parameters, e.g. oxygen saturation, respiratory rate, non-invasive blood pressure and ECG were monitored.

Outcome measures:
VAS score was the primary outcome and it was measured at different time points (1h, 2h, 4h, 6h, 8h, 12h, 18h, and 24 hours postoperatively). The secondary outcome included the effect of these adjuvants on sensory and motor blockade. If the postoperative VAS was higher than 3, it was treated by analgesics such as pethidine.

Complications:
Hypotension was defined as a mean arterial blood pressure (MAP) < 60 mmHg, and it was managed by bolus doses of ephedrine 5 mg and fluids. Bradycardia was defined as heart rate (HR) < 60 b/min, and it was managed by atropine 0.5 mg increments. Vomiting was treated with metoclopramide 10 mg or granisetron 1 mg if persistent.

Statistical Methods:
Results were statistically analyzed by using statistical package of social sciences (SPSS 22.0, IBM/SPSS Inc., Chicago, IL) Two types of statistical analysis were conducted. In all applied tests, the P-values associated with test statistics indicated the significance level at which the null-hypothesis (the hypothesis of no difference) was rejected and it was set at 0.05 so that a P-values ≥ 0.05 are statistically non-significant, P-values < 0.05 are significant, and P-values < 0.01 are highly significant.
RESULTS:

Table 1: General characteristics of cases in the studied groups:

<table>
<thead>
<tr>
<th>Variable</th>
<th>Group A (Fentanyl + bupivacaine) (n= 30)</th>
<th>Group B (Midazolam + bupivacaine) (n= 30)</th>
<th>Group C Bupivacaine (n= 30)</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age</td>
<td>27.24 ± 2.693</td>
<td>26.76 ± 2.457</td>
<td>27.55 ± 2.647</td>
<td>0.251</td>
</tr>
<tr>
<td>BMI</td>
<td>24.26 ± 3.71</td>
<td>25.83 ± 3.24</td>
<td>25.36 ± 3.31</td>
<td>0.354</td>
</tr>
<tr>
<td>ASA score</td>
<td></td>
<td></td>
<td></td>
<td>0.942</td>
</tr>
<tr>
<td>1</td>
<td>27 (90%)</td>
<td>25 (83.3%)</td>
<td>25 (83.3%)</td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>3 (10%)</td>
<td>5 (16.7%)</td>
<td>5 (16.7%)</td>
<td></td>
</tr>
</tbody>
</table>

Continuous data expressed as mean±SD. Categorical data expressed as Number (%)

*: p is significant when <0.05

The demographic criteria of the pregnant females. There was no statistically significant difference in the mean age or the mean BMI among the cases of the three groups (p= 0.251 and 0.354). Most of the cases within the three groups were classified as ASA 1 score (90%, 83.3% and 83.3% in group A, B and C respectively) with no significant difference between the three groups (p=0.942).

Table 2: Sensory block characteristics

<table>
<thead>
<tr>
<th></th>
<th>Group A (Fentanyl + bupivacaine) (n= 30)</th>
<th>Group B (Midazolam + bupivacaine) (n= 30)</th>
<th>Group C Bupivacaine (n= 30)</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mean onset time of sensory blockade at T10 (min)</td>
<td>4.52±0.9</td>
<td>6.86±0.6</td>
<td>8.45±1.3</td>
<td>0.005*</td>
</tr>
<tr>
<td>Maximum sensory level achieved</td>
<td>T5</td>
<td>T6</td>
<td>T6</td>
<td>0.824</td>
</tr>
<tr>
<td>Time to achieve maximum sensory level (min)</td>
<td>9.95±0.6</td>
<td>12.91±0.9</td>
<td>15.25±2.03</td>
<td>0.001*</td>
</tr>
<tr>
<td>Mean time to regression to L1 dermatome (min)</td>
<td>302.44±39.2</td>
<td>215.9±41.5</td>
<td>196.9±33.2</td>
<td>&lt;0.001*</td>
</tr>
</tbody>
</table>

Continuous data expressed as mean±SD. Categorical data expressed as Number (%)

*: p is significant when < 0.05

Group A experienced earlier time of onset regarding sensory blockade at T 10 level (p = 0.005). Moreover, time needed to reach the maximum sensory level was significantly shorter in the same group (p = 0.001). Nevertheless, the maximum sensory level achieved did not differ significantly between the three groups. Group A experienced a significantly longer time for regression of sensory block down to L1 dermatome (p < 0.001).
Comparative Study Between Intrathecal Fentanyl And Midazolam As Adjuvant To Local ….

Table 3: Motor block characteristics.

<table>
<thead>
<tr>
<th></th>
<th>Group A (Fentanyl+ bupivacaine) (n= 30)</th>
<th>Group B (Midazolam+ bupivacaine) (n= 30)</th>
<th>Group C Bupivacaine (n= 30)</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mean onset time of motor block (min)</td>
<td>9.35±0.7</td>
<td>12.04±1.96</td>
<td>13.09±2.84</td>
<td>0.009*</td>
</tr>
<tr>
<td>Maximum Bromage scale</td>
<td>3</td>
<td>3</td>
<td>3</td>
<td>1</td>
</tr>
<tr>
<td>Total duration of motor block (min)</td>
<td>229.2±35.4</td>
<td>181.3±22.5</td>
<td>167.89±29.05</td>
<td>&lt;0.001*</td>
</tr>
</tbody>
</table>

Continuous data expressed as mean±SD; Categorical data expressed as Number (%); *: p is significant when < 0.05.

The mean onset of motor block was also earlier in group A (p = 0.009). Maximum Bromage score did not differ between the three study groups. The total duration of motor blockade was also significantly longer in group A when compared the other two groups (p < 0.001).

Table 4: Basal and post-operative VAS score during rest in the studied groups:

<table>
<thead>
<tr>
<th></th>
<th>Group A (Fentanyl + bupivacaine) (n= 30)</th>
<th>Group B (Midazolam + bupivacaine) (n= 30)</th>
<th>Group C Bupivacaine (n= 30)</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>At PACU</td>
<td>1 (1, 1)</td>
<td>1 (1, 1)</td>
<td>1 (1, 1)</td>
<td>1</td>
</tr>
<tr>
<td>One hour</td>
<td>1 (1, 2)</td>
<td>1 (1, 1)</td>
<td>1 (1, 1)</td>
<td>0.44</td>
</tr>
<tr>
<td>Two hours</td>
<td>1 (1, 1) c</td>
<td>2 (2, 3) c</td>
<td>2 (2, 3) ab</td>
<td>&lt;0.001*</td>
</tr>
<tr>
<td>Four hours</td>
<td>3 (2, 3.50) c</td>
<td>3 (3, 4) c</td>
<td>5 (4, 5) ab</td>
<td>&lt;0.001*</td>
</tr>
<tr>
<td>Six hours</td>
<td>3 (2, 4) b, c</td>
<td>4 (3.50, 4) a,c</td>
<td>4 (3.50, 5.50) ab</td>
<td>&lt;0.001*</td>
</tr>
<tr>
<td>Eight hours</td>
<td>4 (3, 4) b,c</td>
<td>5 (4, 5) a,c</td>
<td>4 (3, 5) ab</td>
<td>&lt;0.001*</td>
</tr>
<tr>
<td>12 hours</td>
<td>4 (3, 4.50) c</td>
<td>4 (4, 5) c</td>
<td>4 (3, 4) ab</td>
<td>0.037*</td>
</tr>
<tr>
<td>18 hours</td>
<td>4 (3, 5) c</td>
<td>4 (4, 5) c</td>
<td>4 (3, 5) ab</td>
<td>0.010*</td>
</tr>
<tr>
<td>24 hours</td>
<td>3 (3, 4)</td>
<td>4 (3, 4)</td>
<td>3 (3, 4)</td>
<td>0.47</td>
</tr>
</tbody>
</table>

Continuous data expressed as median (range); *: p is significant when < 0.05
a: significance in relation to group A; b: significance in relation to group B; c: significance in relation to group C.

There was a statistically significant difference between the females in the three groups in the VAS score after CS. The difference was manifested at two hours up to 18 hours following CS, but no significant difference was detected at 24 hours after the surgery. There was a significant difference between group A and group B at six hours and eight hours with decreased VAS score in group A (Fentanyl + bupivacaine).

Table 5: Post-operative recovery and analgesic requirements in the studied groups:

<table>
<thead>
<tr>
<th></th>
<th>Group A (Fentanyl + bupivacaine) (n= 30)</th>
<th>Group B (Midazolam + bupivacaine) (n= 30)</th>
<th>Group C Bupivacaine (n= 30)</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ambulation (hours)</td>
<td>3.91±1.45</td>
<td>4.09±1.05</td>
<td>3.83±0.72</td>
<td>0.67</td>
</tr>
<tr>
<td>Hospital stay (hours)</td>
<td>14.90±6.54</td>
<td>13.86±4.84</td>
<td>14.07±4.88</td>
<td>0.75</td>
</tr>
<tr>
<td>Pethidine in mg</td>
<td>70.59±11.23 b</td>
<td>80.98±13.54 a</td>
<td>150.31±18.11 a,b</td>
<td>0.003*</td>
</tr>
</tbody>
</table>

Continuous data expressed as mean±SD. *: p is significant when <0.05
a: significance in relation to group A; b: significance in relation to group B.
Ahmed Ali Fawaz, et al.,

There was no significant difference between the females in the three study groups in the ambulation time after surgery, hospital stay (p=0.67 and 0.75). However, there was a statistically significant difference in the mean dose of pethidine in the first day between the three study groups with the least amount required in group A.

Table 6: Neonatal outcomes in the studied groups:

<table>
<thead>
<tr>
<th>Variable</th>
<th>Group A (Fentanyl + bupivacaine) (n= 30)</th>
<th>Group B (Midazolam + bupivacaine) (n= 30)</th>
<th>Group C Bupivacaine (n= 30)</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td>APGAR score (1 min)</td>
<td>7.29 ± 0.53</td>
<td>7.66 ± 0.65</td>
<td>7.51 ± 0.47</td>
<td>0.338</td>
</tr>
<tr>
<td>APGAR score (5 min)</td>
<td>9.45 ± 0.25</td>
<td>9.62 ± 0.16</td>
<td>9.52 ± 0.19</td>
<td>0.276</td>
</tr>
</tbody>
</table>

Continuous data expressed as mean ±SD. Categorical data expressed as Number (%)

*: p is significant when < 0.05

The mean 1 min APGAR score in group A was 7.29 ± 0.53, in group B 7.66 ± 0.65 and 7.51 ± 0.47 in group C with no significant difference between the three groups. The mean 5 min APGAR score in group A was 9.45 ± 0.25, in group B 9.62 ± 0.16 and 9.52 ± 0.19 in group C with no significant difference between the three groups.

**DISCUSSION:**

Spinal anesthesia is preferred over general anesthesia (GA) in cases of cesarean section (CS) delivery, as it avoids the risk of aspiration that may occur with GA, avoids the neonatal depressant effect of GA, and provides postoperative analgesia. However, it also has disadvantages, as it provides a relatively fixed short duration of anesthesia, causes sympathetic block with subsequent hypotension and bradycardia, lesser control on the level of blockade, may give insufficient visceral block with visceral pain, and the possible occurrence of nausea and vomiting especially during uterine manipulation and peritoneal closure (7).

Bupivacaine, which is the most commonly used drug for spinal anesthesia, has slow onset, high potency, and relatively short postoperative analgesia. The intrathecal (IT) dose of hyperbaric bupivacaine for CS ranges from 12 to 15 mg(8).

Peritoneal traction and handling of intraperitoneal organs during cesarean delivery lead to intraoperative visceral pain. Increasing the dose of hyperbaric bupivacaine leads to reduction of the incidence of intraoperative visceral pain, but on the expense of the possibility of the risk of higher blockade and its adverse effects.

To avoid these drawbacks, a number of adjuvants have been used. The commonly used adjuvants include opioids such as fentanyl and nalbuphine; α2 stimulants such as clonidine and dexmedetomidine; NMDA receptor antagonist such as ketamine; GABA receptor agonists such as midazolam (9).

Opioids are the most popular used adjuvants added to bupivacaine in spinal blockade to obtain a sufficient intraoperative visceral analgesia and increase the duration and quality of postoperative analgesia, with less sympathetic block and hemodynamic effect (10).

Fentanyl is a strong µ-opioid receptor agonist. It is a lipophilic opioid, has fast onset of action after IT administration, provides better intraoperative analgesia, and is more safe than morphine for management of early postoperative pain as it does not spread to the fourth ventricle in sufficient
Comparative Study Between Intrathecal Fentanyl And Midazolam As Adjuvant To Local Anesthesia

Intrathecal administration of fentanyl and midazolam is a common practice to enhance the effects of local anesthetics. This study aimed to compare the effects of intrathecal midazolam and fentanyl as additives to intrathecal hyperbaric bupivacaine with respect to onset and duration of sensory block, duration of complete and effective analgesia, and side effects associated with the drug.

Midazolam is a water-soluble benzodiazepine and is extensively used in both critical care medicine and in the operating room for its sedative, anxiolytic, and amnesic effects. Midazolam exerts its analgesic activity through benzodiazepine receptors, which are distributed in the gray matter of the cervical, thoracic, lumbar, and sacral regions of the spinal cord; the highest densities of receptors were localized within lamina II of the dorsal horn. The segmental analgesia produced by intrathecal midazolam is mediated by the benzodiazepine GABA receptor complex, which is also involved in other benzodiazepine actions.

This study was conducted at Ain Shams University Hospitals aiming to evaluate and compare the effects of intrathecal midazolam and fentanyl as additives to intrathecal hyperbaric bupivacaine as regards onset and duration of sensory block, duration of complete and effective analgesia, and side effects associated with the drug. To the best of our knowledge, this is the first study to compare midazolam and fentanyl as adjuvants to bupivacaine in management of postoperative pain following CS.

Starting with demographics in the current study, no significant difference was detected regarding age either while comparing the three groups, or when every two groups are compared separately (p > 0.05). In our study, mean time of onset of sensory blockade in the fentanyl group was 4.52 minutes and it was significantly shorter than the other two groups (p = 0.005) which is 6.86 minutes in midazolam group and 8.45 minutes in bupivacaine group. Moreover, time elapsed till reaching the maximum level of sensory blockade was 9.95 minutes in fentanyl group and 12.9 minutes in midazolam group and 15.25 minutes in bupivacaine group (p = 0.001). In addition, mean time to regression to L1 dermatome was 302.44 minutes in fentanyl group (p < 0.001) and 215.9 minutes in midazolam group and 196.9 in bupivacaine group. Accordingly, time for request of the first analgesia was significantly longer in both adjuvant groups compared to bupivacaine group the third group (p < 0.001), with high superiority of fentanyl against midazolam (p < 0.001).

The extension of the duration of effective analgesia has been well-described before. Prolonged periods of effective analgesia, ranging from 40 to 120 minutes, have been observed for intrathecal fentanyl 6.25 to 12.5 mg in several studies. Nonetheless, most of the research on higher doses of fentanyl has been in agreement, and a prolongation of effective analgesia averaging 3 to 5 hours is in line with our result, has been reported for intrathecal fentanyl at doses of 15 to 25 mg.

As regards midazolam, Dodawad et al. reported that postoperative analgesia was significantly better and longer in the midazolam group as demonstrated by its significantly longer time until the first request for analgesia and also the lower need for rescue analgesics.

Regarding motor block in our study, mean onset of block was achieved after 9.35 minutes in the fentanyl group (p = 0.009) and 12.04 minutes in midazolam group and 13.9 minutes in bupivacaine group. Furthermore, total duration of motor block was significantly longer in fentanyl group which is 229.2 minutes (p < 0.001) and 181.3 minutes in midazolam group and 167.89 minutes in in bupivacaine group.

Bharti et al. reported a prolonged motor block in their midazolam group. The result in our study was in accordance with Muller et al. who reported an antispasticity.
Ahmed Ali Fawaz, et al.,

effect of intrathecal midazolam with little effect on normal motor function.

In our study, both basal and postoperative heart rates and MAP did not differ between the three groups and all of these readings were within the normal heart rate levels. As regards postoperative pain and VAS score the differ between the three groups at PACU and 1-hour after operation (p > 0.05), the fentanyl group expressed significantly lower scores when compared to the other groups (p < 0.05) on the subsequent six readings. Again, no difference was detected 24 hours after operation between the three groups (p > 0.05). Due to longer block and lower VAS scores, the fentanyl group expressed a lower dosage of paracetamol and pethidine intake in the 1st post-operative day when compared to the other groups. The midazolam group received also a lower dose when compared to the third group.

One study reported that when 2 mg intrathecal midazolam were added to 1.5 mL of 5% lignocaine in women who underwent a caesarean section delivery, postoperative pain relief was evident(19). A similar result was shown by Tucker and colleagues(20).

Kim and Lee(21), who reported that the addition of 1 or 2 mg of intrathecal midazolam prolonged the postoperative analgesic effect of bupivacaine by approximately 2 hours and 4.5 hours, respectively, compared with controls after hemorrhoidectomy and used fewer analgesics in the first 24 hours after surgery.

Prakash et al.(22) concluded that 2 mg intrathecal midazolam provided a moderate prolongation of postoperative analgesia in cesarean patients. Similar observations were reported by previous studies(23).

In our study, the detected complications (bradycardia, hypotension, as well as nausea and vomiting) did not differ significantly between the three groups. Moreover, they occurred with a low incidence as no one of

such complications occurred in more than 10% of cases in each group. In addition, these complications were properly managed as discussed in patients and methods. These findings are in agreement with Weigl et al.(24) who showed that the PONV was rare (2/29; 7%) among the patients who received intrathecal fentanyl.

Similar results have been reported in other studies (25, 26, 27). Weigl et al.(24) observed a low incidence of pruritus among the women who received spinal anesthesia with local anesthetic alone, as has been reported in other studies(27).

The incidence of pruritus reached 10% among patients in the fentanyl group, which was also consistent with results of other studies that have reported rates of pruritus ranging from 10% to 24%(27).

Possibly, the most dangerous side effect of opioid analgesia is respiratory depression. Reports of respiratory depression after spinal administration of lipophilic opioids in obstetrics have mostly implicated sufentanil (28), however, no cases have reported the occurance of respiratory depression in our study. Talking about midazolam, this trend is consistent with studies by Sanwal et al.(23) who reported that this relationship may be due to the bupivacaine-sparing effect of midazolam and concluded that intrathecal midazolam may allow the dose of bupivacaine to be reduced while still providing the same surgical anesthesia with fewer episodes of bradycardia and hypotension. A similar observation was reported by previous studies(18, 29, 30).

In our study as regard of the fetal state as assessed by 1 and 5 minutes APGAR scores, there was no significant difference between the three groups. There was no relationship between intrathecal fentanyl administration and neonatal Apgar scores, and this finding is in agreement with those of other studies (15, 27, 14). Adjunct intrathecal midazolam was shown to potentially provide
a more prolonged analgesia than opioids alone while also inhibiting their adverse effects, such as nausea and vomiting (31). It has been postulated that a possible mechanism for the anti-emetic effect of benzodiazepines could be an action at the chemoreceptor trigger zone, which reduce the synthesis, release, and postsynaptic effect of dopamine(32).

**Conclusion:**

From these results we can conclude that:

- Intrathecal adjuvants are associated with improving outcome after CS as revealed by delayed onset and longer duration of sensory and motor block in addition to longer duration of complete and effective analgesia.

- Intrathecal fentanyl revealed better outcomes in terms of delayed onset and longer duration of sensory and motor block in addition to longer duration of complete and effective analgesia as compared with midazolam.

- Addition of intrathecal fentanyl and midazolam didn’t affect the incidence of maternal and fetal complications as compared with bupivacaine alone.

**REFERENCES:**


Comparative Study Between Intrathecal Fentanyl And Midazolam As Adjuvant To Local ....


دراسة مقارنة بين إضافه الفينتانيل والميدازولام إلى دوئية التخدير الموضعي في التخدير الشوكي في عمليات الولادة القصرية الاختيارية وتسكين الألم بعد التدخل الجراحي

أحمد علي فواز، تامر يوسف إيلي، عبد المنعم محمد عبد الوهاب، عبد الرحمن علي جاد مطر
قسم التخدير والرعاية المركزية وعلاج الألم، كلية الطب، جامعة عين شمس

مقدمة البحث: يسم التخدير القطني أو التخدير داخل القراب تاريخ طويل من النجاح حيث أصبح هو الأكثر شيوعاً حيث يرجع ذلك في الغالب إلى زيادة عدد الإجراءات والتدخلات المتصلة التي تتوفر لها التخدير القطني أو النخاعي تخديراً جراحيًا مرتين وتلالاً تابعاً إلى جنب مع صبر المريض ميكاناً والخروج المبكر من المستشفى. أظهرت الدراسات التي تم إجرائها على البوبيفاكايين أنه ينتج تخدير قطني يمكن التنبؤ به وموثوق إليه بالنسبة للعمليات الجراحية.

الهدف من البحث: تهدف هذه الدراسة لإجراء تقييم ومقارنة لآثار الحقن بالميدازولام داخل القراب (2مجم) والحقن بالفينتانيل (25 ميكروجم) كمواد مساعدة كإضافات للحقن بالبوبيفاكاين ضغط ضعيف داخل القراب (0.5%) فيما يتعلق بدائرة وحدة الإحصار الجنسي، مدة التسنين الكامل والفعال، الآثار الجانبية المرتبطة بالحقن بعقاقير التخدير.

طريقة البحث: لقد تمت هذه الدراسة على 90 سيدة (الإصابات الطبيعية تبعاً للباثية البدنية والسيدات اللائي تعانين من مرض جهازي خفيف وفقاً لتصنيف الجمعية الأمريكية لأطباء التخدير) اللائي تراوحت أعمارهن بين 31-50 عام المحدد لهن حالة الولادة القيصرية الاختيارية تحت التخدير القطني. تقسمت المريضات عشوائياً إلى 3 مجموعات (20 مريضة لكل مجموعة): على أساس المواد المساعدة المستخدمة إلى عقاقير التخدير المستخدمة المجموعة الأولى (A): 2مل من البوبيفاكاين ضغط ضعيف 0.5% + 0.4مل من محلول الملح الطبيعي، المجموعة الثانية (B): 2مل من البوبيفاكاين ضغط ضعيف 0.5% + 0.4مل من الميدازولام (2مجم) + 0.1مل من محلول الملح الطبيعي، المجموعة الثالثة (C): 2مل من البوبيفاكاين ضغط ضعيف 0.5% + 0.25مل من الفينتانيل (25 ميكروجم) + 0.25مل من محلول الملح الطبيعي.

نتائج البحث: لم تظهر البيانات الديموغرافية أي اختلاف بين مجموعات الدراسة الثلاث. أظهرت المجموعة A بداية مبكرة للوصول للتسنين الحسي، وكذلك الإحصار المتأخر عند المستوى الحسي عند الفترات المطلوبة الأولى. أظهرت المجموعة الأولى أيضاً مدة أطول في تسنين الألم ووقت أطول قبل استدعاء الأول لمساعدته، كانت الجرعة العاطلية من البارسيتيامول والبيثيدين خلال اليوم الأول أقل بكثير في المجموعة A) والمجموعة B) مقارنة بالمجموعة C). ومع ذلك لم تظهر الملاحظات الثلاث أي اختلاف من حيث المساعدات التي واجهتها السيدات بعد الولادة. وأيضا لم تظهر حالة المواليد أي اختلاف بين المجموعات الثلاث.

خلاصة الدراسة: تم إجراء العملية القصرية بمعدل مرتفع في مصر مع تفضيل التخدير القطني عن التخدير العام. يتم استخدام العديد من المواد المساعدة داخل القراب لتفادي التدخل الخاطئ، ارتبط استخدام المواد المساعدة داخل القراب بالتحسين بعد التدخلات الأمامية، يضيف في مدة الراحة والحركة بالإضافة إلى فترة أطول من المراقبة. أظهرت استخدم الفينتانيل داخل القراب عن نتائج أفضل من حيث مدة الراحة والحركة بالإضافة إلى فترة أطول من المراقبة. إن إضافة الفينتانيل داخل القراب والميدازولام لم يؤثر على حدوث مضاعفات الأم والجنين مقارنة مع بوبيفاكاين وحده.